ReviewInternational journal of oncology2026
mTOR in radiotherapy of lung cancer: Mechanisms of radiation resistance and therapeutic implications (Review).
Review in International journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is an important treatment for tumors; however, some patients exhibit poor sensitivity to radiation, leading to unsatisfactory outcomes. mTOR regulates critical processes such as cell proliferation, autophagy and DNA repair, serving a central role in tumor biology. Moreover, mTOR inhibitors have shown potential to enhance radiotherapy effectiveness and address radiation resistance. Although drug resistance and side effects limit their clinical use, combining therapies and optimizing treatment plans could improve results. The present review summarizes how mTOR signaling contributes to radiation resistance in lung cancer, as well as the underlying molecular mechanisms. Understanding these pathways may aid the development of new combination therapies to improve treatment options for patients with lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.